Floatz logo

Fludarabine

Non-small Cell Lung Cancer, Squamous

PfizerSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Non-small Cell Lung Cancer, Squamous cohort.

Asset / SponsorPhaseRating
Daunorubicin
Pfizer
Phase 2CCC
Cytosin-Arabinosid
Pfizer
Phase 2CCC
ETOPOSIDE
Pfizer
Phase 2CCC
pf-08634404
Pfizer
Phase 2CCC
Calaspargase Pegol
Pfizer
Phase 2CCC
Ladiratuzumab Vedotin
Seagen Inc.
Phase 2CCC
PEGASPARGASE
Pfizer
Phase 2CCC

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi anemiaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Adult Diffuse Large Cell LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →